Every Form 4 that Barinthus Biotherapeutics plc American (BRNS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BRNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRNS filings page.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4/A filing submitted to the SEC.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC.
Barinthus Biotherapeutics plc (BRNS) director Anne M. Phillips reported merger-related dispositions of Barinthus equity on September 9, 2026. Several employee share options to acquire Ordinary Shares, including options over 34,328 shares at $17.00 and 18,604 shares at $4.27, ceased to represent rights in Barinthus and were converted into options over common stock of the acquiring parent company under an Agreement and Plan of Merger. In addition, 3,000 Ordinary Shares were disposed of to Barinthus and each such share was converted into the right to receive 0.111 share of common stock of the parent. No Rule 10b5-1 trading plan is reported, and no remaining Barinthus derivative positions are listed.
Barinthus Biotherapeutics plc (BRNS) director Pierre A. Morgon reported several dispositions of securities on September 9, 2026, in connection with the closing of a merger under an Agreement and Plan of Merger. Barinthus became a direct wholly owned subsidiary of a new parent company at the merger’s effective time.
On that date, multiple share options to acquire Barinthus ordinary shares, with exercise prices ranging from $0.0001 to $17.00 per share and expiring between 2030 and 2035, were reported as dispositions to the issuer and converted into options over the parent company’s common stock on the same terms. In addition, 10,506 ordinary shares (which may be held as ADSs) were reported as disposed to the issuer as each Barinthus share was converted into the right to receive 0.111 shares of the parent company’s common stock. No Rule 10b5-1 trading plan is reported.
Barinthus Biotherapeutics plc (BRNS) reported that Chief Medical Officer Leon Hooftman’s equity awards in Barinthus were restructured on September 9, 2026 in connection with the closing of a previously agreed merger. Two options to acquire a total of 335,166 Ordinary Shares were disposed of to Barinthus and, under the merger terms, each such option ceased to represent a right to acquire Barinthus shares and was converted into an option over common stock of the acquiring parent company. In addition, 361,530 restricted share units and the related Ordinary Shares were reported as acquired and then disposed of at the same Effective Time, reflecting that these RSUs were automatically released and assumed as RSUs over the parent company’s common stock. No Rule 10b5-1 trading plan is reported.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC. Hammacher Alex reported disposition transactions in this Form 4 filing.
Barinthus Biotherapeutics plc (BRNS) reports that director Alex Hammacher’s Barinthus equity awards and shares were restructured on September 9, 2026 in connection with the completion of a merger under an Agreement and Plan of Merger. Several option grants over Barinthus ordinary shares ceased to be rights over Barinthus stock and were converted into options over common stock of the new parent company, while 3,000 Barinthus ordinary shares were exchanged, with each Barinthus share converted into the right to receive 0.111 share of the parent’s common stock.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC.
Barinthus Biotherapeutics plc. (symbol: BRNS) is the issuer of record for a Form 4 filing submitted to the SEC.